Business Wire

XPENG To Attend IAA Mobility 2023 as EU Deliveries Begin

30.8.2023 13:45:00 EEST | Business Wire | Press release

Share

XPeng Motors (“XPENG” or the “Company,” NYSE: XPEV and HKEX: 9868), a leading Chinese smart electric vehicle (“Smart EV”) company, today announced the beginning of P7 deliveries in four key European markets and its participation in IAA Mobility 2023, Munich, Germany.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230830333578/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

European P7 Delivery

Outstanding Smart EVs for Europe

XPENG G9 and P7 were launched in February this year, with excitement around the brand and positive feedback continuing to build up with deliveries beginning.

In June, XPENG G9 broke the charging record at the two-day NAF (Norwegian Automobile Federation) and Motor EV Summer test, also known as El-Prix 2023, reaching a peak charging power of 319 kW. This also represented the test's highest average charging power at 212 kW, allowing drivers to charge up to 100 km of range in just five minutes. G9 and P7 occupied the top two spots in the range test, which measures the real-world deviation rate compared to the stated WLTP range; there was an increase of 13% and 10% for G9(4WD) and P7(4WD), respectively.

As a spacious sports sedan, XPENG P7's cabin provides exceptional comfort, which is surrounded by a sleek exterior epitomizing XPENG's Dynamic Aesthetics design language. Deliveries of P7 recently commenced, with the first batches of vehicles having arrived at XPENG's delivery centers in Lørenskog, Norway; Järfälla, Sweden; Hillerød, Denmark; and Badhoevedorp, The Netherlands.

"We’re delighted that customers who placed orders at the very beginning can finally drive P7 on Europe’s roads,” said Eric Xu, VP of International Markets XPENG. “The feedback has been positive so far, and with our rapidly growing network, we’re very optimistic about our future on the continent.”

Drive With Confidence

As part of the company's dedication to delivering superior customer experiences, XPENG is offering a comprehensive service agreement, which includes an eight-year warranty for the vehicle's battery, as well as a seven-year/160,000 km extended warranty for all orders placed in 2023.

Deliveries of G9 will begin in the coming months as XPENG's network of authorized agencies and partners expands, which will optimize sales, delivery, and servicing processes to create a seamless customer journey.

Learn More About XPENG P7 for Europe

https://www.heyxpeng.com/nl/p7

https://www.heyxpeng.com/dk/p7

https://www.heyxpeng.com/no/p7

https://www.heyxpeng.com/se/p7

XPENG at IAA Mobility 2023

As a technology pioneer in the mobility industry, XPENG will participate in the world's largest mobility event this year, IAA Mobility, on September 4–10, 2023 in Munich. XPENG's agenda is as follows:

  • Pre-IAA XPENG Press Conference
    • H4 Hotel Munich Messe
    • Monday, September 4, 11 am–12 pm
  • IAA Summit Panel: Unleashing the Integrated Smart Ecosystem
    • Blue Stage
    • A discussion on how intelligent and autonomous vehicles are transforming the industry and our overall mobility experience
    • Featuring Co-President and Vice Chairman Brian Gu
    • Tuesday, September 5, 3 pm–3:45 pm
  • Open Space Activation with Product Displays
    • Konigsplatz, Stand KP155
    • Tuesday, September 5 – Sunday, September 10, 10 am–8 pm
  • P7 and G9 Test Drives at Blue Lane*
    • Near Hall C3, Munich Messe
      • Monday, September 4, 8 am–6 pm
      • Tuesday, September 5 – Friday, September 8, 9 am–6 pm
    • Near Konigsplatz
      • Tuesday, September 5 – Saturday, September 9, 10 am–8 pm
      • Sunday, September 10, 10 am–5 pm

*Subject to pre-booking

Follow XPENG at IAA Mobility 2023

Instagram

LinkedIn

Twitter

Facebook

About XPENG

XPENG is a global smart electric vehicle company founded in 2014 in Guangzhou, China, developing clean, intuitive, and creative mobility solutions. With industry-leading R&D facilities, XPENG is bringing vehicles with superior safety, electric efficiency, and on-road performance to markets across the globe. The company is constantly working to advance its core technology offering, including autonomous driving capabilities, SEPA 2.0, and captivating in-car infotainment systems. XPENG has headquarters in Guangzhou and Amsterdam, with additional offices in Beijing, Shanghai, and Silicon Valley.

Visit heyxpeng.com for more information.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For Media Enquiries: pr@xiaopeng.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Mosaic Clinical Technologies Announces FDA Breakthrough Device Designation for Cognita’s Generative AI Model for Radiology5.3.2026 09:00:00 EET | Press release

Mosaic Clinical Technologies™, a wholly-owned subsidiary of Radiology Partners, is pleased to announce that Cognita™, its AI business unit developing generative vision-language models (VLMs) for radiology, has received U.S. Food and Drug Administration (FDA) Breakthrough Device Designation for Cognita Chest X-Ray (CXR)™1 across multiple critical indications. Cognita CXR is an industry-first generative vision-language model designed to assist radiologists in the interpretation of chest X-rays and is the first radiology generative AI model, and one of very few radiology AI solutions, to be granted this designation2. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304633206/en/ Cognita™ operates as the AI business unit of Mosaic Clinical Technologies™, a wholly owned subsidiary of Radiology Partners, the largest radiology practice in the U.S, with more than 4,000 radiologists in its network. Cognita CXR1 applies a proprietary

SOLUM and Simbe Expand European Collaboration to Advance Intelligent Store Operations5.3.2026 09:00:00 EET | Press release

SOLUM (KOSPI: 248070) and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. The collaboration was highlighted at EuroShop, where Simbe’s Store Intelligence™ platform was demonstrated live at the SOLUM booth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304620371/en/ SOLUM and Simbe announced the expansion of their strategic collaboration to further integrate autonomous store intelligence with SOLUM’s Newton Electronic Shelf Label (ESL) infrastructure across Europe. (Image: SOLUM) Simbe recently introduced Tally 4.0, the next generation of their autonomous shelf-scanning robot, reflecting the company’s continued evolution in retail shelf digitization, incorporating extended runtime, enhanced edge computing, and advanced vision capabilities. Designed to deliver deeper shelf coverag

Cielo Advances Resilient Remote Connectivity for Its Nationwide Payment Terminal Fleet With Thales5.3.2026 09:00:00 EET | Press release

For Cielo, connectivity is mission critical. When payment terminals lose network access, transactions stop. To strengthen operational resilience and enhance merchant experience, Cielo is modernizing its connectivity architecture across its terminal fleet. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260304089321/en/ Cielo advances resilient remote connectivity for its nationwide payment terminal fleet with Thales. Using Thales’s eSIM technology as part of this strategy, Cielo can remotely switch mobile network operators over the air in just a few seconds, without sending a technician and with minimal disruption to merchants’ activity. For merchants, the experience is seamless: if a network becomes unstable, the payment terminal can automatically reconnect to another available network, often without the merchant even noticing. This deployment represents one of the first large-scale implementations of the SGP.32 eSIM specifi

GAIA and Daiichi Sankyo Europe Enter Exclusive Partnership to Launch Next-Generation Digital Therapeutic for Cardiovascular Care in Europe.5.3.2026 09:00:00 EET | Press release

GAIA, the pioneer in evidence-based digital therapeutics and Daiichi Sankyo Europe, today announced an exclusive strategic partnership to commercialize lipodia upon regulatory approval1. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224658973/en/ Dr. Mario Weiss, Founder & CEO of GAIA AG This digital therapeutic is designed to support adults living with hypercholesterolemia. The comprehensive collaboration brings together GAIA’s long-standing expertise in developing clinically validated non-pharmacological interventions with Daiichi Sankyo’s highly scientific experience in cardiovascular risk management and health. Together, the partners - both members of the German Association of Research-Based Pharmaceutical Companies (vfa) - aim to address a persistent gap in chronic care: leveraging digital technologies to make a difference in patients’ lives by supporting sustainable, long-term behaviour change. Expanding Cardiovasc

Galderma Delivers Record 2025 Results With Net Sales of 5.207 Billion USD, up 17.7% at Constant Currency 1 , and Core EBITDA 2 of 1.211 billion USD, Growing 18.9% at Constant Currency5.3.2026 08:00:00 EET | Press release

Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the full year 2025. Record net sales of 5,207 million USD, surpassing 5 billion USD in a year for the first time and representing 17.7% year-on-year growth on a constant currency1 basis, primarily driven by volume. Broad-based net sales growth, growing double-digits in both International markets and the U.S. Outperforming the market in each product category, with strong net sales growth in Injectable Aesthetics (11.5%), Dermatological Skincare (9.3%) and Therapeutic Dermatology (50.2%), all year-on-year at constant currency. Strong launch momentum across future growth drivers, including Nemluvio® (nemolizumab) delivering 452 million USD in net sales; Relfydess™ (RelabotulinumtoxinA) outperforming expectations in 17 International markets; Sculptra® gaining significant market share in its first year in China; and continued new product launches across Galderma’s full portfoli

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye